A method for preparing nanobodies against carcinoembryonic antigen
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of nano-antibody and antigen, applied in the field of preparation of antibody protein
Active Publication Date: 2021-05-04
深圳市国创纳米抗体技术有限公司
View PDF2 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Due to the unique characteristics of nanobodies in terms of molecular weight and spatial structure, it is difficult to express them compared with traditional Kluyveromyces lactis. So far, there has been no report on the expression of nanobodies against carcinoembryonic antigen (Anti-CEA) in yeast cells.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0030] Example 1. Preparation of Nanobodies Against Carcinoembryonic Antigen
[0033] According to the sequence that can detect the CEA gene obtained from the previous screening, the nucleotide sequence was optimized (SEQ ID NO. 1) without changing the amino acid sequence (SEQ ID NO. 2), and then based on the expression of Kluyveromyces lactis Based on the characteristics of the multi-cloning site of the vector pKLAC2, the following pair of primers were designed and synthesized:
[0038] Both ends of pKL1 and pKL2 are designed with NotI and EcoRI restriction sites respectively (see the lowercase and underlined parts in the above sequence)
[0039] 1.2 PCR amplification of Anti-C...
Embodiment 2
[0086] Example 2. Affinity determination of Kluyveromyces lactis-expressing nanobody 11C12 protein against carcinoembryonic antigen
[0087]The affinity of Nanobodies against carcinoembryonic antigen was tested by direct coupling method (Biacore). The carcinoembryonic antigen used Recombinant Carcino Embryonic Antigen CEA protein (Abcam, product number is ab99235).
[0088] Prepare 20ug / ml of anti-carcinoembryonic antigen nanobodies with running buffer as the sample on the machine, select pH=1.5 glycine hydrochloride system, use the template method that comes with the instrument, and set the parameters as follows: injection time 60 seconds, flow rate 30ul / min, dissociation time 600s, regeneration time 30s, flow rate 30ul / min, the affinity of anti-carcinoembryonic antigen nanobodies to carcinoembryonic antigen was tested. like Image 6 As shown, the affinity of the nanobody against carcinoembryonic antigen measured by the direct coupling method was 5.042×10 -9 .
[0089] se...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
molecular weight
aaaaa
aaaaa
capacitance
aaaaa
aaaaa
electrical resistance
aaaaa
aaaaa
Login to view more
Abstract
The invention provides a method for preparing a nanobody against carcinoembryonic antigen, said method comprising the following steps: (1) amplifying the coding gene of the carcinoembryonic antigen nanobody; (2) converting the coding gene obtained in step (1) to Linked to the expression vector pKLAC2; (3) transducing the vector obtained in step (2) into the host cell Kluyveromyces lactis; (4) inducing the host cell obtained in step (3), and harvesting the expressed anti-carcinoembryonic antigen nano Antibody. The invention also provides an expression vector containing the anti-carcinoembryonic antigen nanobody and a host cell Kluyveromyces lactis containing the vector. Using the method of the present invention, the expressed nanobody is secreted to the outside of the cell, the foreign protein is less, and the target band detected by Western Blot is single, thereby reducing the cost of separation and purification, and greatly improving the efficiency of expression; Under the conditions of bottle culture, the amount of extracellular secretion was 0.8 mg / l, and the affinity of the nanobody against carcinoembryonic antigen measured by direct coupling method was 5.042×10 ‑9 .
Description
technical field [0001] The present invention relates to a method for preparing an antibody protein, and more particularly to a method for preparing a nanobody protein using Kluyveromyces lactis. Background technique [0002] Carcinoembryonic antigen (CEA, also known as CEACAM-5 or CD66e) is a glycoprotein with a molecular weight of about 180 kDa. CEA, a member of the immunoglobulin superfamily, was originally classified as a protein expressed only in fetal tissues and has now been identified in normal adult tissues. Overexpression of CEA has been detected in colorectal, pancreatic, lung, gastric, hepatocellular, breast, and thyroid cancers. Therefore, CEA has been identified as a tumor-associated antigen, while CEA has also been used as a tumor marker, and immunological assays measuring elevated CEA in the blood of cancer patients have been used clinically for cancer prognosis and control. [0003] At present, CEA has become a potential tumor-associated antigen for targete...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more